

FORM 2B

LISTING SUMMARY

Issuer Name: Biocure Technology Inc.			Listing Statement Date: November 22, 2017	
Descriptions of securities to be listed: Common Shares				
Address: Suite 950-1130 West Pender Street, Vancouver, BC, Canada V6E 2T5			Brief Description of the Issuer's Business: Biopharmaceutical company specializing in the development and commercialization of biosimilars	
Company Contact: Sang Goo (Collin) Kim			Description of securities outstanding	
Phone: 778-331-3815			Symb of CURE	Type Common
			Number 93,387,632	CUSIP 09075T107
Fax: 604.685.5120			If the Listing Statement was required to be filed because an event giving rise to material information has occurred that makes the previous Statement inaccurate or misleading, briefly describe the event: March 22, 2017 and August 30, 2017	
E-mail: collinkim_in_ca@yahoo.ca			Dates of Press Release and Any Public Filings Concerning the Event:	
Jurisdiction of Incorporation: British Columbia			Date of Last Shareholders' Meeting and Date of Next Shareholders' Meeting (if scheduled):	
Website: www.biocuretech.com				
Fiscal Year End: December 31				
Financial Information as at : [Date] June 30			Board of Directors: See below	
	[Current]	[Previous]	Name	Position
Current Assets	\$3,375	\$6,326	Sang Mok Lee	President, CEO and Director
Working Capital	(\$109,143)	(\$87,409)	Nizar Bharmal	CFO and Director
Total assets	\$1,968,902	\$1,971,853	Sang Goo (Collin) Kim	Director
Long-term liabilities	N/A	N/A	Julie Hajduk	Director
Shareholders' equity	\$1,856,384	\$1,878,118	Anna Dalairé	Director